RxDoctor Payments Data

Alexis McAfee

Nurse Practitioner · Jacksonville, FLNPI 1538812318

Payments from drug & device makers

$6,902in general payments, 2019–2025

Across 340 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$948
  • AbbVie$591
  • AstraZeneca$587
  • Lilly USA, LLC$522
  • GSK$504
  • Novo Nordisk$455
  • plus $3K from 31 others

What the payments were for

  • Food & beverage$6,902100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,902 in reported general payments places this provider in the 95th percentile of 8,290 nurse practitioner providers in Florida.

See all nurse practitioner providers in Florida

Medicare billing

Part B allowed, 2024
$64,005
Medicare patients
272
Services billed
1,600

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide65$88,147
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$32,472
MounjaroTirzepatide19$28,254
FarxigaDapagliflozin Propanediol16$18,652
EliquisApixaban15$16,136
Rosuvastatin Calcium113$1,417
Omeprazole72$1,325
Nifedipine ErNifedipine36$1,191
Telmisartan41$1,184
Atorvastatin Calcium99$1,088
Nebivolol Hcl19$1,026
Gabapentin43$873
Albuterol Sulfate HfaAlbuterol Sulfate36$838
Fenofibrate29$765
Fluticasone Propionate37$670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$455$88,14765 claims
GSKTrelegy Ellipta$504$32,47232 claims
Lilly USA, LLCMounjaro$522$28,25419 claims
AstraZenecaFarxiga$587$18,65216 claims
PfizerEliquis$295$16,13615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,290 nurse practitioner providers in Florida.

Other nurse practitioner in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →